دورية أكاديمية
أعرض في EDS

In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity.

التفاصيل البيبلوغرافية
العنوان: In major dysmood disorder, physiosomatic, chronic fatigue and fibromyalgia symptoms are driven by immune activation and increased immune-associated neurotoxicity.
المؤلفون: Maes M; Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. dr.michaelmaes@hotmail.com.; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China. dr.michaelmaes@hotmail.com.; Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand. dr.michaelmaes@hotmail.com.; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria. dr.michaelmaes@hotmail.com.; Research Institute, Medical University Plovdiv, Plovdiv, Bulgaria. dr.michaelmaes@hotmail.com.; Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul, 02447, Korea. dr.michaelmaes@hotmail.com., Almulla AF; Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, and King Chulalongkorn Memorial Hospital, The Thai Red Cross Society, Bangkok, Thailand.; Medical Laboratory Technology Department, College of Medical Technology, The Islamic University, Najaf, Iraq., Zhou B; Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China.; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China., Algon AAA; Research Group of Organic Synthesis and Catalysis, University of Pannonia, Egyetem u. 10, Veszprém, 8200, Hungary., Sodsai P; Department of Immunology, Faculty of Medicine, Center of Excellence in Immunology and Immune-Mediated Diseases, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
المصدر: Scientific reports [Sci Rep] 2024 Mar 28; Vol. 14 (1), pp. 7344. Date of Electronic Publication: 2024 Mar 28.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : Nature Publishing Group, copyright 2011-
مواضيع طبية MeSH: Depressive Disorder, Major* , Fatigue Syndrome, Chronic* , Fibromyalgia*, Humans ; Cytokines ; Interleukins ; Chemokines
مستخلص: Major depressive disorder (MDD) is accompanied by activated neuro-immune pathways, increased physiosomatic and chronic fatigue-fibromyalgia (FF) symptoms. The most severe MDD phenotype, namely major dysmood disorder (MDMD), is associated with adverse childhood experiences (ACEs) and negative life events (NLEs) which induce cytokines/chemokines/growth factors. To delineate the impact of ACE + NLEs on physiosomatic and FF symptoms in first episode (FE)-MDMD, and examine whether these effects are mediated by immune profiles. ACEs, NLEs, physiosomatic and FF symptoms, and 48 cytokines/chemokines/growth factors were measured in 64 FE-MDMD patients and 32 normal controls. Physiosomatic, FF and gastro-intestinal symptoms belong to the same factor as depression, anxiety, melancholia, and insomnia. The first factor extracted from these seven domains is labeled the physio-affective phenome of depression. A part (59.0%) of the variance in physiosomatic symptoms is explained by the independent effects of interleukin (IL)-16 and IL-8 (positively), CCL3 and IL-1 receptor antagonist (inversely correlated). A part (46.5%) of the variance in physiosomatic (59.0%) symptoms is explained by the independent effects of interleukin (IL)-16, TNF-related apoptosis-inducing ligand (TRAIL) (positively) and combined activities of negative immunoregulatory cytokines (inversely associated). Partial least squares analysis shows that ACE + NLEs exert a substantial influence on the physio-affective phenome which are partly mediated by an immune network composed of interleukin-16, CCL27, TRAIL, macrophage-colony stimulating factor, and stem cell growth factor. The physiosomatic and FF symptoms of FE-MDMD are partly caused by immune-associated neurotoxicity due to T helper (Th)-1 polarization and M1 macrophage activation and relative lowered compensatory immunoregulatory protection.
(© 2024. The Author(s).)
References: Cells. 2022 May 07;11(9):. (PMID: 35563878)
Pharmaceuticals (Basel). 2022 Mar 26;15(4):. (PMID: 35455402)
CNS Drugs. 2014 Jan;28(1):1-10. (PMID: 24150993)
Brain Sci. 2023 Jul 14;13(7):. (PMID: 37509005)
Mol Neurobiol. 2020 Aug;57(8):3334-3348. (PMID: 32514863)
CNS Neurol Disord Drug Targets. 2023;22(2):215-225. (PMID: 35946099)
Psychiatry Clin Neurosci. 2023 Feb;77(2):125-126. (PMID: 36454120)
Immunol Lett. 2018 Dec;204:29-37. (PMID: 30321562)
Brain Res. 2006 Sep 13;1109(1):83-92. (PMID: 16836983)
Biology (Basel). 2021 May 27;10(6):. (PMID: 34071825)
Mol Neurobiol. 2019 Sep;56(9):6626-6644. (PMID: 30911933)
Mol Psychiatry. 2018 Jan;23(1):48-58. (PMID: 29133955)
J Neuroinflammation. 2013 Jul 17;10:85. (PMID: 23866312)
J Adv Res. 2023 Nov 13;:. (PMID: 37967811)
Psychiatry Res. 2024 Apr;334:115812. (PMID: 38442479)
Am J Psychiatry. 2011 Dec;168(12):1266-77. (PMID: 22193671)
J Investig Med. 2009 Aug;57(6):703-8. (PMID: 19240648)
J Biol Chem. 2016 Aug 5;291(32):16840-8. (PMID: 27231345)
J Psychosom Res. 2002 Jun;52(6):501-9. (PMID: 12069875)
J Pers Med. 2022 Mar 05;12(3):. (PMID: 35330403)
Acta Psychiatr Scand. 2014 Feb;129(2):83-97. (PMID: 23952563)
J Pers Med. 2022 Jan 01;12(1):. (PMID: 35055338)
Pharmacol Res. 2019 Oct;148:104450. (PMID: 31509764)
J Affect Disord. 2020 Dec 1;277:940-948. (PMID: 33065836)
J Gerontol B Psychol Sci Soc Sci. 2002 Jan;57(1):P87-94. (PMID: 11773227)
Expert Opin Ther Targets. 2014 May;18(5):495-512. (PMID: 24548241)
Immunology. 2000 May;100(1):63-9. (PMID: 10809960)
Mol Neurobiol. 2014 Apr;49(2):741-56. (PMID: 24068616)
Cells. 2022 Mar 31;11(7):. (PMID: 35406747)
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14470-5. (PMID: 10588729)
Adv Healthc Mater. 2022 Oct;11(20):e2201203. (PMID: 35856921)
Psychoneuroendocrinology. 1995;20(2):111-6. (PMID: 7899532)
Am J Psychiatry. 1999 Jun;156(6):837-41. (PMID: 10360120)
Mol Psychiatry. 2023 Feb;28(2):564-578. (PMID: 36280755)
Prog Neuropsychopharmacol Biol Psychiatry. 1993 Mar;17(2):241-55. (PMID: 8430217)
Nitric Oxide. 2021 Jan 1;106:45-54. (PMID: 33186727)
J Affect Disord. 2023 Jun 15;331:300-312. (PMID: 36996718)
Lancet Psychiatry. 2016 Apr;3(4):342-9. (PMID: 26873185)
Neurotox Res. 2018 Apr;33(3):641-655. (PMID: 29380275)
BMC Psychiatry. 2022 May 31;22(1):369. (PMID: 35641947)
Acta Neuropsychiatr. 2023 Dec;35(6):328-345. (PMID: 37052305)
Brain Res. 2009 May 7;1269:54-60. (PMID: 19285486)
Metab Brain Dis. 2021 Mar;36(3):509-521. (PMID: 33411213)
CNS Neurol Disord Drug Targets. 2023;22(2):191-206. (PMID: 35366785)
Brain Sci. 2023 Apr 24;13(5):. (PMID: 37239186)
J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62. (PMID: 14399272)
Inflammopharmacology. 2012 Jun;20(3):127-50. (PMID: 22271002)
Brain Res Bull. 1990 Jun;24(6):849-52. (PMID: 2196977)
Nat Med. 2002 Feb;8(2):157-65. (PMID: 11821900)
Psychol Med. 2023 Sep;53(12):5839-5851. (PMID: 36254747)
Cell Mol Immunol. 2020 Dec;17(12):1281-1283. (PMID: 32210394)
Prostaglandins Leukot Essent Fatty Acids. 2013 Oct;89(5):351-8. (PMID: 24055573)
Med Hypotheses. 2012 Nov;79(5):607-13. (PMID: 22951418)
Br J Psychiatry. 1980 Apr;136:339-46. (PMID: 7388241)
iScience. 2022 May 18;25(6):104426. (PMID: 35663027)
Acta Neuropsychiatr. 2023 Apr;35(2):104-117. (PMID: 36380512)
Biomol Concepts. 2018 Nov 20;9(1):115-130. (PMID: 30471214)
Exp Gerontol. 2018 Feb;102:109-132. (PMID: 29237576)
Int J Environ Res Public Health. 2022 Aug 19;19(16):. (PMID: 36011997)
Prog Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):664-75. (PMID: 20599581)
Behav Brain Res. 2016 Feb 1;298(Pt B):218-28. (PMID: 26589802)
Br J Med Psychol. 1959;32(1):50-5. (PMID: 13638508)
J Clin Virol. 2014 Jun;60(2):105-11. (PMID: 24742598)
J Affect Disord. 2022 Jan 15;297:233-245. (PMID: 34699853)
Am J Prev Med. 1998 May;14(4):245-58. (PMID: 9635069)
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Jan 10;36(1):169-75. (PMID: 21945535)
Int J Mol Sci. 2022 Oct 01;23(19):. (PMID: 36232931)
J Affect Disord. 2022 Feb 1;298(Pt A):194-201. (PMID: 34715193)
Am J Physiol Gastrointest Liver Physiol. 2008 Mar;294(3):G770-7. (PMID: 18202111)
Metab Brain Dis. 2012 Dec;27(4):415-23. (PMID: 22614823)
Psychol Med. 1992 Feb;22(1):45-53. (PMID: 1574566)
Acta Psychiatr Scand. 2013 May;127(5):344-54. (PMID: 22900942)
Med Hypotheses. 2012 Jun;78(6):752-6. (PMID: 22445460)
Mol Neurobiol. 2018 Dec;55(12):8885-8903. (PMID: 29611101)
Acta Psychiatr Scand. 2017 May;135(5):373-387. (PMID: 28122130)
J Affect Disord. 2013 Sep 5;150(2):223-30. (PMID: 23664637)
معلومات مُعتمدة: HEA663000016 The Thailand Science Research, and Innovation Fund at Chulalongkorn University; RA66/016 Sompoch Endowment Fund (Faculty of Medicine) MDCU; 64.310/436/2565 The C2F program at Chulalongkorn University in Thailand
فهرسة مساهمة: Keywords: Affective disorders; Chronic fatigue syndrome; Inflammation; Major depression; Neuro-immune; Stress
المشرفين على المادة: 0 (Cytokines)
0 (Interleukins)
0 (Chemokines)
تواريخ الأحداث: Date Created: 20240328 Date Completed: 20240329 Latest Revision: 20240330
رمز التحديث: 20240330
مُعرف محوري في PubMed: PMC10973347
DOI: 10.1038/s41598-024-57350-1
PMID: 38538641
قاعدة البيانات: MEDLINE
كن أول من يترك تعليقا!
يجب تسجيل دخولك أولا